Quote:

---

Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency

---

It might be useful in the HIV subpopulation with the duel CCR5/CXCR4 variation but I have my doubts. They are almost certainly using the original formulation of leronlimab instead of the newer concentrated formulation. Which means you are not going to get 100% receptor occupancy in CCR5 unless you have multiple doses a week instead of one dose. You also have the problem that some of that dose is going to be split off to occupy CXCR4. So it could be daily doses or even a shorter dosage schedule. Since it would do the same as the concentrated leronlimab combined with a CXCR4 blocker it would actually be a step backwards.